Isolated Adrenocorticotropic Hormone Deficiency Secondary to Pembrolizumab-Induced Hypophysitis: A Case of Life-Threatening Adrenal Crisis in a Patient With Metastatic Melanoma
Abstract
Immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD-1) inhibitors, can cause endocrine immune-related adverse events, including hypophysitis and secondary adrenal insufficiency. Isolated adrenocorticotropic hormone (ACTH) deficiency is uncommon but may present as a life-threatening adrenal crisis. We report the case of a 65-year-old man with stage IV BRAF wild-type metastatic melanoma receiving pembrolizumab who presented with profound fatigue, nausea, vomiting, weight loss, orthostatic dizziness, and hypotension. Laboratory evaluation revealed severe hyponatremia, mild hyperkalemia, hypoglycemia, and acute kidney injury. Serum cortisol was 2.1 µg/dL with an inappropriately low ACTH concentration of <5 pg/mL. A conventional 250 µg cosyntropin (Synacthen) stimulation test demonstrated an inadequate cortisol response, while other pituitary axes remained preserved. Pituitary magnetic resonance imaging showed mild enlargement and stalk thickening, consistent with hypophysitis. Intravenous hydrocortisone and fluid resuscitation rapidly restored hemodynamic and metabolic stability. At 6 months, ACTH remained <5 pg/mL, with persistent isolated corticotroph deficiency. Pembrolizumab-associated isolated ACTH deficiency should be considered when patients develop unexplained constitutional symptoms, hypotension, hyponatremia, or hypoglycemia. Prompt cortisol and ACTH assessment and glucocorticoid treatment are essential to prevent morbidity and mortality.
Related
- Arginine vasopressin deficiency following pembrolizumab-induced hypophysitis: a case report and review of the literature
- Probable Hypophysitis Recognized More Than Two Years After Pembrolizumab Discontinuation
- Immunotherapy with Pembrolizumab beyond Progression and Local Ablative Therapy in Oligoprogressive Metastatic Non-Small Cell Lung Cancer
- Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study.
BibTeX
@article{sherzodbek2026isolated,
title = {{Isolated Adrenocorticotropic Hormone Deficiency Secondary to Pembrolizumab-Induced Hypophysitis: A Case of Life-Threatening Adrenal Crisis in a Patient With Metastatic Melanoma}},
author = {Tashbaev Sherzodbek and Mamatov Hurshidbek Mirzakamol o‘g‘li and Azizbek Mutalipov and Ozodbek Eshqobilov and Tareq Nayef AlRamadneh and Mohammad Adi and Ahmed Ashraf},
journal = {Clinical Medicine Insights: Endocrinology and Diabetes},
year = {2026},
month = oct,
doi = {10.1177/11795514261502021},
url = {https://doi.org/10.1177/11795514261502021},
note = {CC BY},
}
RIS
TY - JOUR
TI - Isolated Adrenocorticotropic Hormone Deficiency Secondary to Pembrolizumab-Induced Hypophysitis: A Case of Life-Threatening Adrenal Crisis in a Patient With Metastatic Melanoma
AU - Tashbaev Sherzodbek
AU - Mamatov Hurshidbek Mirzakamol o‘g‘li
AU - Azizbek Mutalipov
AU - Ozodbek Eshqobilov
AU - Tareq Nayef AlRamadneh
AU - Mohammad Adi
AU - Ahmed Ashraf
PY - 2026
DA - 2026/10/23
JO - Clinical Medicine Insights: Endocrinology and Diabetes
DO - 10.1177/11795514261502021
UR - https://doi.org/10.1177/11795514261502021
AB - Immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD-1) inhibitors, can cause endocrine immune-related adverse events, including hypophysitis and secondary adrenal insufficiency. Isolated adrenocorticotropic hormone (ACTH) deficiency is uncommon but may present as a life-threatening adrenal crisis. We report the case of a 65-year-old man with stage IV BRAF wild-type metastatic melanoma receiving pembrolizumab who presented with profound fatigue, nausea, vomiting, weight loss, orthostatic dizziness, and hypotension. Laboratory evaluation revealed severe hyponatremia, mild hyperkalemia, hypoglycemia, and acute kidney injury. Serum cortisol was 2.1 µg/dL with an inappropriately low ACTH concentration of <5 pg/mL. A conventional 250 µg cosyntropin (Synacthen) stimulation test demonstrated an inadequate cortisol response, while other pituitary axes remained preserved. Pituitary magnetic resonance imaging showed mild enlargement and stalk thickening, consistent with hypophysitis. Intravenous hydrocortisone and fluid resuscitation rapidly restored hemodynamic and metabolic stability. At 6 months, ACTH remained <5 pg/mL, with persistent isolated corticotroph deficiency. Pembrolizumab-associated isolated ACTH deficiency should be considered when patients develop unexplained constitutional symptoms, hypotension, hyponatremia, or hypoglycemia. Prompt cortisol and ACTH assessment and glucocorticoid treatment are essential to prevent morbidity and mortality.
SN - 1179-5514
ER -